INDV Q1 2024 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$284M+12.3% YoY

Gross Profit

$246M86.6% margin

Operating Income

$75M26.4% margin

Net Income

$61M21.5% margin

EPS (Diluted)

$0.45

QoQ Revenue Growth

-3.1%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$57M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$1.4B

Stockholders' Equity

$10M

Cash & Equivalents

$248M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$284M	$253M	+12.3%
Gross Profit	$246M	$214M	+15.0%
Operating Income	$75M	$57M	+31.6%
Net Income	$61M	$44M	+38.6%